Company intelligence / Profile preview

O.M.A.R.

Seattle, Washington, United Statesomar.house.gov ↗

Ownership: Private
Employees: ~202
Development stage: Other

Overview

Omeros has a diverse pipeline with lead candidate narsoplimab (OMS721/MASP‑2) for TA-TMA in late-stage development. OMS1029 completed Phase I for MASP‑2/lectin pathway disorders. Zaltenibart is in Phase III for PNH and Phase II for C3G. OMS527 completed early-phase studies targeting addiction/movement disorders. The company previously commercialized OMIDRIA® before divesting it.

Therapeutic areas: NephrologyHematologyPsychiatryNeurologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibodyProtein therapeutics
Industry: Biotech

Beyond the preview

Go deeper on O.M.A.R..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on O.M.A.R..

Explore the full profile